Order results by:
| Issue | Title | |
| Vol 18, No 6 (2022) | Effect of ABCB1 Gene Carriage and Drug-Drug Interactions on Apixaban and Rivaroxaban Pharmacokinetics and Clinical Outcomes in Patients with Atrial Fibrillation and Deep Vein Thrombosis | Abstract similar documents |
| L. V. Fedina, I. N. Sychev, T. D. Rastvorova, E. V. Strigunkova, A. A. Kachanova, Z. A. Sozaeva, P. O. Bochkov, A. V. Vardanyan, K. B. Mirzayev, D. A. Sychev | ||
| "... . Мы обнаружили, что у пациентов – носителей генотипа CT+TT ABCB1 (rs4148738) C>T, кодирующего белок-переносчик ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... влияния генотипа на фармакокинетику ривароксабана. У носителей полиморфизма rs4148738 гена ABCB ..." | ||
| Vol 16, No 5 (2020) | Pharmacokinetics and Pharmacogenetics of Apixaban | Abstract similar documents |
| A. V. Savinova, M. M. Petrova, N. A. Shnayder, E. N. Bochanova, R. F. Nasyrova | ||
| "... -окисления апиксабана (CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2J2) и белков-транспортеров (ABCB1, ABCG2) в его ..." | ||
| Vol 20, No 1 (2024) | Effect of CYP3A4/5, ABCB1 gene polymorphisms on the residual equilibrium concentration of apixaban and bleeding in patients with non-valvular atrial fibrillation and deep vein thrombosis | Abstract similar documents |
| l. V. Fedina, i. N. Sychev, K. V. Mirzaev, A. V. Vardanyan, S. V. Glagolev, A. A. Kachanova, P. O. Bochkov, R. V. Shevchenko, S. N. Tuchkova, I. V. Sychev, S. P. Abdullaev, D A. Sychev | ||
| "... 3A5*3 (c.219-237A>G, rs776746), ABCB1 rs1045642 (c.3435T>C) и rs4148738 (c.2692-2236C>T) на плазменную ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| "... for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| "... rivaroxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomized ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... блокаторы тромбина (дабигатран), либо блокаторы IIа фактора (апиксабан, ривароксабан, эдоксабан). Согласно ..." | ||
| Vol 13, No 1 (2017) | CLINICAL AND ECONOMICAL COMPARISON OF RIVAROXABAN AND APIXABAN USE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Nedogoda, I. N. Barykina, A. S. Salasiuk, V. O. Smirnova | ||
| "... и апиксабана у пациентов с неклапанной фибрилляцией предсердий (ФП) и оценить влияние двух видов терапии ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| "... The opinion is expressed in some domestic publications that rivaroxaban has the most favorable ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... . Direct oral anticoagulants, particularly rivaroxaban, are widely used for deep vein thrombosis/pulmonary ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... препаратами (ацетилсалициловая кислота) и новыми пероральными антикоагулянтами (апиксабан, ривароксабан ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... практике. Приводятся данные о лекарственных взаимодействиях апиксабана, ривароксабана и дабигатрана ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| "... применение апиксабана сопровождается наилучшей приверженностью среди всех новых пероральных антикоагулянтов ..." | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... , требующих назначения антагонистов витамина К (варфарина) или новых пероральных антикоагулянтов (апиксабана ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| "... антикоагулянтов с особым акцентом на их безопасности. Пероральный ингибитор Ха фактора апиксабан на данный момент ..." | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... нового поколения, включающих дабигатран, ривароксабан и апиксабан, с позиции безопасности терапии ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... 57,7% (384/665) больных ФП: ривароксабан - 180 (46,9%), дабигатран - 110 (28,6%) больных, апиксабан ..." | ||
| Vol 14, No 2 (2018) | NEW DIRECT ORAL ANTICOAGULANTS FOR TREATMENT OF PATIENTS WITH ATRIAL FIBRILLATION IN REAL-WORLD SETTING | Abstract similar documents |
| Zh. D. Kobalava, S. V. Villevalde, A. A. Shavarov | ||
| "... сравнении трех ПОАК между собой апиксабан отличается более низким риском геморрагических осложнений, тогда ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... – ривароксабан и апиксабан), были включены в когортное исследование в параллельных группах. Помимо оценки ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... пациенты ≥75 лет с подтвержденной ФП, получающие дабигатран в сниженной дозе, апиксабан или ривароксабан ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... принимали 38,5% (n=166), ривароксабан – 41,3% (n=178), апиксабан – 20,2% (n=87) пациентов. Результаты ..." | ||
| Vol 16, No 2 (2020) | Off-Label Medicines Use: Complex Problem of Modern Clinical Practice | Abstract similar documents |
| S. R. Gilyarevskiy | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... the direct oral anticoagulant rivaroxaban showed a tendency to reduce the risk of thromboembolism ..." | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| "... on rivaroxaban has changed — instead of "use with caution", as stated in the previous document from 2019 ..." | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 17, No 6 (2021) | Anticoagulants after Discharge in Patients with COVID-19: What we Know at the End of 2021 | Abstract similar documents |
| I. S. Yavelov | ||
| "... . The first prospective randomized controlled trial MICHELLE with direct oral anticoagulant rivaroxaban ..." | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... препаратами (ацетилсалициловая кислота) и новыми пероральными антикоагулянтами, к которым относятся апиксабан ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... Новые пероральные антикоагулянты, ингибирующие фактор Xa (ривароксабан, апиксабан, эдоксабан) или ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... терапии, поскольку исследования с дабигатраном и апиксабаном II и III фазы были признаны неудачными ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... дабигатрана, прямых ингибиторов Xа фактора свёртывания ривароксабана и апиксабана в лечении неклапанной формы ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... пероральных антикоагулянтов (дабигатрана, ривароксабана, апиксабана и эдоксабана) над антагонистом витамина ..." | ||
| Vol 16, No 2 (2020) | The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment | Abstract similar documents |
| К. V. Lobastov, I. V. Schastlivtsev | ||
| "... (апиксабан), CARAVAGGIO (апиксабан). Ривароксабан продемонстрировал бóльшую эффективность при сопоставимом ..." | ||
| Vol 16, No 4 (2020) | The Controversy Continues Again: which Direct Anticoagulant is More Effective and Safe when Administered to Patients with Atrial Fibrillation? | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... апиксабану в способности предупреждать ишемический инсульт, системную эмболию и чаще вызывает кровотечения ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... , ривароксабана, апиксабана и эдоксабана. Основным осложнением любой антикоагулянтной терапии являются ..." | ||
| Vol 21, No 2 (2025) | Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, M. I. Chashkina, E. S. Zadykyan, N. K. Kurbanalieva, E. M. Zakaryan, M. V. Serova, D. A. Andreev, A. G. Komarova, K. E. Eroshkin, A. A. Kulesh, D. A. Sychev | ||
| "... на амбулаторном этапе: ривароксабан (n=56), апиксабан (n=30), дабигатрана этексилат (n=11), варфарин ..." | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... ривароксабан (36,7%), 30,6% респондентов был назначен апиксабан, и почти в два раза реже по сравнению ..." | ||
| Vol 21, No 5 (2025) | Plasma concentrations of factor Xa inhibitors and stroke risk in patients with atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, P. O. Bochkov, M. I. Chashkina, L. V. Fedina, N. A. Shatalova, E. R. Khayrutdinov, K. B. Mirzaev, N. M. Krivosheeva, K. E. Eroshkin, A. G. Komarova, D. A. Andreev, D. A. Sychev | ||
| "... с ФП без инсульта и транзиторной ишемической атаки, пациенты обеих групп получали ПОАК (апиксабан или ..." | ||
| Vol 21, No 4 (2025) | Pleiotropic properties of direct oral anticoagulants — new therapeutic horizons | Abstract similar documents |
| P. A. Davtian, N. S. Zagidullin | ||
| "... Прямые оральные антикоагулянты (ПОАК), включая ингибиторы фактора Xa (ривароксабан, апиксабан ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... и апиксабана при подготовке и проведении электрической кардиоверсии у больных с неклапанной ФП. Во всех ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... появилась целая группа новых ОАК (НОАК). В России зарегистрированы дабигатран, ривароксабан и апиксабан. Все ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... и 3 (4,4%) – апиксабана по 5 мг 2 р/сут. Повторное чреспищеводное эхокардиографическое исследование выполнялось в среднем ..." | ||
| Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
| "... и 43 (21,4%) – апиксабана. Во время визита В1 по результатам шкалы приверженности НОДФ абсолютно привержены ..." | ||
| 1 - 52 of 52 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
.jpg)
